5-(Difluoromethoxy)-2-mercapto-1H-benzimidazole

We are 5-(Difluoromethoxy)-2-mercapto-1H-benzimidazole CAS:97963-62-7 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:5-(Difluoromethoxy)-2-mercapto-1H-benzimidazole
CAS.NO:97963-62-7
Synonyms:5-(Difluoromethoxy)-2-mercapto-1H-benzimidazole
5-difluoromethoxy-2-mercapto-1H-benzimidazole
5-(DIFLUOROMETHOXY)-2-BENZIMIDAZOLETHIOL
5-(difluoromethoxy)-1H-benzo[d]imidazole-2-thiol
5-Difluoromethoxy-1H-benzimidazole-2-thiol
 
Physical and Chemical Properties:
Density 1.5±0.1 g/cm3
Boiling Point 360.9±50.0 °C at 760 mmHg
Melting Point 239-243 °C(lit.)
Molecular Formula C8H6F2N2OS
Molecular Weight 216.208
Flash Point 172.1±30.1 °C
 
Specification:
Appearance:Off-white to pale yellow powder
Assay:≥98.0%
Loss on drying:≤1.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Pantoprazole(CAS:102625-70-7).

5-(Difluoromethoxy)-2-mercapto-1H-benzimidazole


Related News: Pharmaceutical intermediates and APIs belong to the fine chemical industry.1H,1H,2H,2H-Perfluorooctyltriethoxysilane CAS:51851-37-7 This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?102691-36-1 This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?1-(2,3,5-Tri-O-acetyl-beta-D-ribofuranosyl)-1H-1,2,4-triazole-3-carboxylic acid, methyl ester Remogliflozin is economical than other similar agents currently available in sodium glucose co-transporter-2 (SGLT2) inhibitors class, which shall help for its better access among middle and low socio-economic strata of the society, he added.Remogliflozin is economical than other similar agents currently available in sodium glucose co-transporter-2 (SGLT2) inhibitors class, which shall help for its better access among middle and low socio-economic strata of the society, he added.

Related Products
Product Name
decyl prop-2-enoate View Details
3,4,5-Trifluoronitrobenzene View Details
5′-Tosyl Adenosine View Details
(6-Hydroxynaphthalen-2-yl)boronic acid manufacturer Linoleic acid manufacturer 3-Bromo-2-fluoropyridine manufacturer (2R,3S)-N-Benzoyl-3-phenyl Isoserine manufacturer (4S)-4-benzyl-1,3-oxazolidine-2,5-dione manufacturer